By Fineline Cube Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for HS-10504, a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The designation supports development for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients harboring EGFR C797S mutations following disease progression on prior EGFR-TKI therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) |
| Product | HS-10504 – fourth-generation EGFR TKI |
| Regulatory Agency | Center for Drug Evaluation (CDE), NMPA China |
| Designation | Breakthrough Therapy Designation (BTD) |
| Target Population | NSCLC patients with EGFR C797S mutations post-EGFR-TKI progression |
| Disease Stage | Locally advanced or metastatic NSCLC |
| Development Stage | Clinical development (specific phase not disclosed) |
Drug Profile & Mechanism of Action
- Molecule Class: Fourth-generation EGFR tyrosine kinase inhibitor (TKI)
- Target Mutation: EGFR C797S mutation – a key resistance mechanism to third-generation EGFR inhibitors
- Therapeutic Rationale: Addresses critical unmet need in NSCLC patients who have exhausted current EGFR-TKI options
- Innovation: Represents next-generation approach to overcome resistance mutations that render existing therapies ineffective
- Competitive Positioning: Among the first fourth-generation EGFR inhibitors to receive BTD in China
Clinical Development Context
| Aspect | Significance |
|---|---|
| Resistance Challenge | EGFR C797S mutation is primary resistance mechanism to osimertinib and other third-generation EGFR TKIs |
| Patient Population | Estimated 15–20% of NSCLC patients develop C797S-mediated resistance after third-generation TKI treatment |
| Current Treatment Options | Limited effective therapies; primarily chemotherapy or clinical trial participation |
| Regulatory Pathway | BTD provides expedited review, intensive guidance, and potential priority approval |
| Global Race | Part of international competition to develop fourth-generation EGFR inhibitors for resistant NSCLC |
The Breakthrough Therapy Designation reflects the significant unmet medical need for effective treatments in NSCLC patients who develop resistance to current standard-of-care EGFR inhibitors through C797S mutations.
Market Implications & Strategic Outlook
- China NSCLC Landscape: NSCLC represents approximately 85% of all lung cancer cases in China, with EGFR mutations present in 30–40% of patients
- Treatment Sequencing Opportunity: HS-10504 could become standard third-line therapy following progression on first- and third-generation EGFR TKIs
- Commercial Potential: Addressable market of 20,000–30,000 Chinese NSCLC patients annually with C797S resistance mutations
- Global Expansion Strategy: Success in China could facilitate international regulatory submissions and partnership opportunities
- Hansoh’s Oncology Portfolio: Strengthens company’s position as leading Chinese innovator in targeted cancer therapies
- Competitive Timeline: Places Hansoh among global leaders in fourth-generation EGFR inhibitor development
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory designations, clinical development, and market opportunities for HS-10504. Actual results may differ due to risks including clinical trial outcomes, regulatory review processes, competitive developments, and market dynamics in the oncology space.-Fineline Info & Tech